SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: PawPr who wrote (655)4/15/1998 11:54:00 AM
From: SG  Read Replies (2) | Respond to of 965
 
My impression is that Crohn's patients have normal life span, similar life insurance rates. Wouldn't it (life span) be lower if they were subject to lymphomas at significantly higher rates? The influence of prior immunosuppressant drugs is, of course, a factor, but if one develops lymphoma immediately following Avakine regimen, one would certainly want to r/o a cause-effect relationship.

SG



To: PawPr who wrote (655)4/18/1998 2:01:00 PM
From: Robohogs  Read Replies (1) | Respond to of 965
 
Monday is the day for earnings - not much expected given all cross-currents:
- Retevase charge
- Offering
- Other

But everyone will key on Reopro sales, the LLY conference call, and the CNTO conference call. Specifically, guidance on sales trends, forecasts and MRK and CORR attacks on market. Good luck.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News